BlackRock Health Sciences Term Trust (NYSE:BMEZ) Director Sells $154,204.12 in Stock

BlackRock Health Sciences Term Trust (NYSE:BMEZ) Director Robert Fairbairn sold 10,294 shares of the stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $14.98, for a total transaction of $154,204.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

BlackRock Health Sciences Term Trust Stock Down 0.1%

NYSE:BMEZ traded down $0.01 during trading hours on Monday, hitting $15.17. 204,842 shares of the company were exchanged, compared to its average volume of 305,926. BlackRock Health Sciences Term Trust has a 52-week low of $12.58 and a 52-week high of $16.75. The company’s 50 day moving average price is $15.04 and its 200-day moving average price is $14.57.

BlackRock Health Sciences Term Trust Announces Dividend

The company also recently announced a monthly dividend, which will be paid on Wednesday, December 31st. Stockholders of record on Monday, December 22nd will be issued a dividend of $0.11 per share. This represents a c) annualized dividend and a dividend yield of 8.7%. The ex-dividend date of this dividend is Monday, December 22nd.

Institutional Investors Weigh In On BlackRock Health Sciences Term Trust

Large investors have recently modified their holdings of the business. Royal Bank of Canada lifted its stake in shares of BlackRock Health Sciences Term Trust by 326.9% in the first quarter. Royal Bank of Canada now owns 1,594,157 shares of the company’s stock worth $23,753,000 after buying an additional 1,220,764 shares in the last quarter. Bank of America Corp DE raised its holdings in BlackRock Health Sciences Term Trust by 4.1% in the 3rd quarter. Bank of America Corp DE now owns 1,535,091 shares of the company’s stock valued at $22,136,000 after acquiring an additional 61,105 shares during the last quarter. Penserra Capital Management LLC lifted its stake in BlackRock Health Sciences Term Trust by 15.2% in the 3rd quarter. Penserra Capital Management LLC now owns 1,332,633 shares of the company’s stock worth $19,216,000 after purchasing an additional 175,629 shares in the last quarter. Invesco Ltd. boosted its holdings in shares of BlackRock Health Sciences Term Trust by 42.7% during the 3rd quarter. Invesco Ltd. now owns 929,121 shares of the company’s stock worth $13,398,000 after purchasing an additional 278,024 shares during the last quarter. Finally, Readystate Asset Management LP grew its position in shares of BlackRock Health Sciences Term Trust by 664.6% in the third quarter. Readystate Asset Management LP now owns 247,074 shares of the company’s stock valued at $3,563,000 after purchasing an additional 214,761 shares in the last quarter.

BlackRock Health Sciences Term Trust Company Profile

BlackRock Health Sciences Term Trust (NYSE: BMEZ) is a closed-end management investment company organized as a Delaware statutory trust. Launched in March 2020, BMEZ seeks to provide total return through a combination of current income and capital appreciation by investing primarily in equity and equity-related securities of companies in the health sciences sector. The trust is structured with a fixed termination date in October 2030, at which time shareholders will vote on its liquidation, extension or conversion.

The fund’s investment portfolio is diversified across subsectors within health sciences, including biotechnology, pharmaceuticals, medical devices, diagnostics and healthcare services.